Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024
2016 ESMO CongressMartin Reck, MD, PhD, of the LungenClinic, discusses study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)
Related Videos
Alain Ravaud, MD, PhD, on RCC: Results of the S-TRAC Trial (French Language Version)
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses in French phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after n...
Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024 (German Language Version)
Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung ca...
Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results (Italian Language Version)
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses in Italian overall survival and safety results from a phase 3 trial of ipilimumab at 3 mg/kg vs 1...
Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abst...
Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial (Italian Language Version)
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses in Italian study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non–sma...
